Management in multimorbidity: glucocorticoid-induced hyperglycemia and diabetes in rheumatic diseases
DOI:
https://doi.org/10.52556/2587-3873.2024.5(102).06Keywords:
glucocorticosteroids, diabetes, hyperglycemia, rheumatic diseasesAbstract
Glucocorticoids (GC) are drugs with an important antiinflammatory and immunosuppressive effect, being recommended in treating autoimmune diseases, but which have a series of metabolic side effects, including diabetes. The purpose of the research is to highlight the possibilities of monitoring and treating hyperglycemia and diabetes mellitus (DM) induced by glucocorticoids in patients with rheumatic diseases to optimize the management of these patients. A literature review on the management of glucocorticoid-induced hyperglycemia and diabetes was performed. The databases searched were PubMed, Medline, Web of Science. The MeSh terms were „corticosteroid-induced hyperglycemia” OR „corticosteroidinduced diabetes” AND (rheumatic diseases). 26 sources were identified and analyzed. American and British Diabetic Society guidelines for the diagnosis and management of glucocorticoid-induced hyperglycemia and diabetes aim largely at hospitalized patients, and subsequent outpatient follow-up is inconclusive. At the initiation of GC therapy, it is recommended to assess the basal blood glucose in hospitalized people with DM, four times a day postprandial, and in patients who are not known to have diabetes - once a day. With the development of steroid-induced DM, oral antidiabetics will be recommended, and in cases when patients present significant hyperglycemia in association with signs of diabetic ketoacidosis or hyperosmolar hyperglycemic state, the recommendations of the international guidelines are to initiate insulin. After stopping the administration of GC, the blood sugar will be constantly and repeatedly monitored, together with the review of the hypoglycemic therapy and the achievement of normoglycemia during 3 months, and if it persists, the blood sugar will be monitored after 3 months, together with the performance of the oral glucose tolerance test or HbA1c.
References
1. LIU, XX et al. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. In: Ann Nutr Metab. 2014, nr. 65(4), pp. 324-32. PMID: 25402408 https://doi.org/10.1159/000365892
2. NARWANI, V., SWAFE, L., STAVRAKA, C., DHATARIYA, K. How frequently are bedside glucose levels measured in hospital inpatients on glucocorticoid treatment? In: Clin Med. 2014, nr. 14(3), pp. 327-8. PMID: 24889595; PMCID: PMC4952563. https://doi.org/10.7861/clinmedicine.14-3-326a
3. FARDET, L., PETERSEN, I., NAZARETH, I. Monitoring of patients on long-term glucocorticoid therapy: a population-based cohort study. In: Medicine. 2015, nr. 94(15), e647. PMCID: PMC4602514. https://doi.org/10.1097/MD.0000000000000647
4. ROBERTS, A., JAMES, J., DHATARIYA, K. Joint British Diabetes Societies (JBDS) for Inpatient Care. Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. In: Diabet Med. 2018, nr. 35(8), pp. 1011-7. PMID: 30152586. https://doi.org/10.1111/dme.13675
5. BONAVENTURA, A., MONTECUCCO, F. Steroid-induced hyperglycemia: an underdiagnosed problem or clinical inertia? A narrative review. In: Diabetes Res Clin Pract. 2018, nr. 139, pp. 203-20. PMID: 29530386. https://doi.org/10.1016/j.diabres.2018.03.006
6. FATHALLAH, Neilla et al. Drug-induced hyperglycaemia and diabetes. In: Drug Saf. 2015, nr. 38(12), pp. 1153-68. PMID: 26370106. https://doi.org/10.1007/s40264-015-0339-z
7. VEGIOPOULOS, A. & HERZIG, S. Glucocorticoids, metabolism and metabolic diseases. In: Mol. Cell. Endocrinol, 2007, nr. 275, pp. 43-61 PMID: 17624658 https://doi.org/10.1016/j.mce.2007.05.015
8. PUIGSERVER, P. et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. In: Nature. 2003, nr.423, pp. 550-555. PMID: 12754525 https://doi.org/10.1038/nature01667
9. BUREN, J., LIU, H.X., JENSEN, J., ERIKSSON, J.W. Dexamethasone impairs insulin signalling and glucose transport by depletion of insulin receptor substrate-1, phosphatidylinositol 3-kinase and protein kinase B in primary cultured rat adipocytes. In: Eur. J. Endocrinol. 2002, Nr. 146, pp. 419-429. PMID: 11888850 https://doi.org/10.1530/eje.0.1460419
10. RUZZIN, J., WAGMAN, A.S., JENSEN, J. Glucocorticoidinduced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. In: Diabetologia. 2005, nr. 48, pp. 2119-2130. PMID: 16078016. https://doi.org/10.1007/s00125-005-1886-0
11. WILLIAM, L., HOLLAND, J., BROZINICK, T. et.al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. In: Cell Metab. 2007, nr. 5(3), pp. 167-179. PMID: 17339025 https://doi.org/10.1016/j.cmet.2007.01.002
12. CHONG, XU., JINHAN, HE., HONGFENG J. et al. Direct effect of glucocorticoids on lipolysis in adipocytes. In: Mol.Endocrinol. 2009, nr. 23(8), pp. 1161-70. PMID: 19443609 https://doi.org/10.1210/me.2008-0464
13. SAKODA, H. et al. Dexamethasone-induced insulin resistance in 3T3-L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction. In: Diabetes 2000, nr. 49, pp. 1700-1708. PMID: 11016454. https://doi.org/10.2337/diabetes.49.10.1700
14. LI, J.X., CUMMINS, C. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. In: Nat Rev Endocrinol. 2022, nr. 18(9), pp. 540-557. doi: 10.1038/s41574-022-00683-6. https://doi.org/10.1038/s41574-022-00683-6
15. SINAGA, G., DE KOEIJER, E. Management of dexamethasone- induced hyperglycemia in patients undergoing chemotherapy in an outpatient setting: a best practice implementation project. In: JBI Database Syst Rev Implement Rep. 2018, nr. 16(4), pp. 1068-78. PMID: 29634519. https://doi.org/10.11124/JBISRIR-2017-003466
16. BLACKBURN, D., HUX, J., MAMDANI, M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. In: J Gen Intern Med. 2002, nr. 17(9), pp. 717-20. PMID: 12220369. https://doi.org/10.1046/j.1525-1497.2002.10649.x
17. CAPLAN, F., ROSENBACH, W. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Ocular, cardiovascular, muscular, and psychiatric side effects. In: J Am Water Works As soc [Internet]. PMID: 28088991 Disponibil pe: https://www.sciencedirect.com/science/article/pii/.
18. FARDET, L., PETERSEN, I., NAZARETH, I. Prevalence of longterm oral glucocorticoid prescriptions in the UK over the past 20 years. In: Rheumatology. 2011, nr. 50(11), pp. 1982-90. ISSN 1462-0324. https://doi.org/10.1093/rheumatology/ker017
19. Tamez-Pérez H.E., Quintanilla-Flores D.L., RodríguezGutiérrez R. et al. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. In: World J Diabetes. 2015 Jul 25;6(8):1073-81. PMID: 26240704. https://doi.org/10.4239/wjd.v6.i8.1073
20. MILLS, E., DEVENDRA, S. Steroid-induced hyperglycaemia in primary care. In: Lond J Prim Care (Abingdon). 2015, nr. 7(5), pp. 103-6. PMID: 26550039. https://doi.org/10.1080/17571472.2015.1082344
21. JOHARATNAM-HOGAN, N. et al. Joint British Diabetes Society for Inpatient Care (JBDS), UK Chemotherapy Board (UKCB). A guideline for the outpatient manage ment of glycaemic control in people with cancer. In: Diabet Med. 2022, nr. 39(1), e14636.PMID: 34240470. https://doi.org/10.1111/dme.14636
22. GULLIFORD, M.C., CHARLTON, J., LATINOVIC, R. Risk of diabetes associated with prescribed glucocorticoids in a large population. In: Diabetes Care. 2006, nr. 29(12), pp. 2728-9. PMID: 17130196, https://doi.org/10.2337/dc06-1499
23. SHAH, P. et al. Management of GlucocorticoidInduced Hyperglycemia. In: Diabetes Metab Syndr Obes. 2022, nr. 23(15), pp. 1577-88. PMID: 35637859.
24. SIMMONS, L. et al. Steroid-induced diabetes: is it just unmasking of type 2 diabetes? In: ISRN Endocrinol. 2012, nr. 5(2012), 910905. PMID: 22830041. https://doi.org/10.5402/2012/910905
25. WU, J. et al. Glucocorticoid Dose-Dependent Risk of Type 2 Diabetes in Six Immune-Mediated Inflammatory Diseases: A Population-Based Cohort Analysis. In: SSRN Electron J. Disponibil pe: . PMID: 32719077.
26. FARDET, L., PETERSEN, I., NAZARETH, I. Risk of cardio vascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study.In: BMJ. 2012, nr. 30(345), e4928. PMID: 22846415; https://doi.org/10.1136/bmj.e4928
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
